EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers

Kyosuke Seguchi iD, Tadayoshi Hashimoto iD, Takao Fujisawa, Akitaka Makiyama, Toshihiro Kudo, Kentaro Yamazaki, Koushiro Ohtsubo, Taroh Satoh iD, Chigusa Morizane, Shogen Boku iD, Eiji Oki iD, Naoki Takahashi und 14 weitere

Cancer Science · 11.11.2026

DOI: 10.1111/cas.70594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 11.11.2026. Verfasst von Kyosuke Seguchi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, SCRUM-Japan MONSTAR-SCREEN Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AXL, a receptor tyrosine kinase, has been implicated in epithelial–mesenchymal transition, angiogenesis, immune evasion, and therapeutic resistance, but its relevance in upper gastrointestinal cancers remains incompletely defined. We analyzed 337 patients with advanced gastric ( n = 287) or esophageal ( n = 50) cancer enrolled in SCRUM‐Japan MONSTAR‐SCREEN‐2, whose tumors were profiled by whole‐exome and whole‐transcriptome sequencing. Patients were classified as AXL ‐high ( n = 169) or AXL ‐low ( n = 168) using cancer type‐specific median transcripts‐per‐million cutoffs. Median follow‐up was 14.1 months. AXL ‐high tumors were associated with shorter overall survival than AXL ‐low tumors (median, 12.9 versus 17.1 months; hazard ratio, 1.58; 95% confidence interval, 1.17–2.14; p = 0.003), consistently in gastric (hazard ratio, 1.47; p = 0.020) and esophageal (hazard ratio, 2.46; p = 0.027) cancer. This association persisted after adjustment for cancer type, age, sex, number of metastatic sites, microsatellite instability status, and tumor mutational burden (hazard ratio, 1.59; 95% confidence interval, 1.14–2.22; p = 0.007). Among microsatellite stable patients treated with immune checkpoint blockade, AXL expression was not associated with progression‐free survival (hazard ratio, 0.83; 95% confidence interval, 0.61–1.14; p = 0.255). AXL ‐high tumors showed stromal and vascular expansion, regulatory T‐cell enrichment, higher expression of fibroblast growth factor receptor 1, vascular endothelial growth factor receptors 1–3, and MET , and enrichment of epithelial–mesenchymal transition, angiogenesis, and transforming growth factor beta signaling. High AXL expression identifies a poor‐prognosis stromal‐angiogenic phenotype in upper gastrointestinal cancers and warrants prospective validation as a prognostic, rather than predictive, biomarker. Trial Registration: UMIN Clinical Trials Registry, UMIN000043899

Schlagwörter

Stichwörter der Autor:innen

AXL receptor tyrosine kinaseesophageal neoplasmsprognosisstomach neoplasmstumor microenvironment

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Cancer Center, Gifu University Hospital, Gifu, Japan.
  • Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

ORCID-Profile: Kyosuke Seguchi, Tadayoshi Hashimoto, Taroh Satoh, Shogen Boku, Eiji Oki, Yoshito Komatsu, Hideaki Bando, Takayuki Yoshino

Förderung

  • NCI NIH HHS
  • SCRUM-Japan MONSTAR-SCREEN Fund

Zitieren

APA

Seguchi, K., Hashimoto, T., Fujisawa, T., Makiyama, A., Kudo, T., Yamazaki, K., Ohtsubo, K., Satoh, T., Morizane, C., Boku, S., Oki, E., Takahashi, N., Nagashima, F., Kadowaki, S., Kato, T., Komatsu, Y., Kubota, Y., Tsuji, A., Fukuda, Y., …, & Yoshino, T. (2026). High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers. Cancer Science. https://doi.org/10.1111/cas.70594

Vancouver

Seguchi K, Hashimoto T, Fujisawa T, Makiyama A, Kudo T, Yamazaki K, et al. High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers. Cancer Science. 2026. doi:10.1111/cas.70594

BibTeX
@article{Seguchi2026,
  author = {Seguchi, Kyosuke and Hashimoto, Tadayoshi and Fujisawa, Takao and Makiyama, Akitaka and Kudo, Toshihiro and Yamazaki, Kentaro and Ohtsubo, Koushiro and Satoh, Taroh and Morizane, Chigusa and Boku, Shogen and Oki, Eiji and Takahashi, Naoki and Nagashima, Fumio and Kadowaki, Shigenori and Kato, Takeshi and Komatsu, Yoshito and Kubota, Yohei and Tsuji, Akihito and Fukuda, Yukiko and Iida, Naoko and Shibuki, Taro and Bando, Hideaki and Ashouri, Karam and Algaze, Sandra and Lenz, Heinz-Josef and Yoshino, Takayuki},
  title = {High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70594}
}
Kostenlos starten →